The Mold Treatment Breakthrough We Didn’t Expect
In a Nutshell
**Aggressive pharmaceutical antifungals like posaconazole at therapeutic blood levels are required to eliminate resistant fungal infections, as herbs alone are insufficient and subtherapeutic dosing worsens inflammation and resistance.** Success depends on five principles: diagnostic clarity using symptoms, history, antibodies, and CT scans; achieving verified therapeutic drug concentrations through blood testing rather than standard dosing; avoiding low-dose "start slow" approaches that provoke resistance; and ensuring drugs reach all target tissues including sinuses and intestinal basement membrane. Combining systemic antifungals with non-absorbable agents like Amphotericin B addresses both systemic and luminal infections to reduce the 20-50% relapse rates.
These notes were generated by AI and may contain inaccuracies.
This talk is directed to those who have tried other interventions, such as probiotics, herbs and diet, and have not succeeded. After extensive research on this topic over the past two years, the conclusion is that it is easy to fail in the context of people who have not responded to the basics. In the age of artificial intelligence, many of the current recommendations in the field of integrative medical treatment for fungal infections have been validated, and areas where further improvement is possible have been discovered.
The first principle is diagnostic clarity. It is necessary to find out if the right thing is being dealt with. It seems obvious, but some of these tests are likely to be wrong. The second principle is that herbs are not enough. Herbs are an important part of this situation to help with treatment, inflammation, and biofilms. However, colleagues have become convinced that herbs alone are not enough in this context. Adding pharmaceutical antifungals may be very important. But the drugs must reach targeted therapeutic levels. This is extremely important because some of these antifungal drugs do not have good absorption. Therefore, a 200 mg dose cannot be assumed to achieve the same blood level in different people.
The fourth concept is not to be hesitant on the battlefield. There is emerging and compelling data suggesting that if treatment is not aggressive enough, more symptoms of fungal death or infections will actually be experienced. Inflammation is made worse, but at the same time an infection that is more resistant to treatment could be promoted. The fifth and final point is that treatments must reach the target tissues. This was very revealing when delving into pharmaceutical research; not all drugs reach different tissues, for example, the small intestine versus the large intestine. Therefore, if these five principles are applied effectively, a significant impact can be made on the outcomes in eliminating fungal infections and getting rid of the burden of these symptoms.
Michael Russo is a physician in private practice, an assistant professor, and a clinical researcher. He sees patients, teaches students, and publishes research, all in the fields of integrative and functional medicine. Dr. Scott Spirit Lewsey serves as the Director of Clinical Care at the clinic and is a wealth of information on fungi. Both have been, and to some extent still are, suffering from a fungal infection. They not only live within this experience and try to find a way out of it, but they delve deeper into research and apply what they learn in the clinic.
Academically, research is looked at. Clinically, experiments are conducted on themselves. These things are implemented in the clinic, and feedback is received from themselves and from the patients they work with. AI-enhanced attention has allowed every recommendation within the current mold and fungus treatment model to be validated and verified. Some things seem like the best way to deal with this, and others do not.
This is intended for people who know or suspect they are infected, and really want to get to the heart of the matter: how to confirm the diagnosis and, most importantly, how to treat it successfully. Distinctive digestive signs include bloating, abdominal distension, diarrhea, constipation, and gas. This is not a comprehensive list. These are just some of the most relevant and prominent neurological symptoms: fatigue, brain fog, anxiety, and depression. Sinus symptoms include red eyes, itchy eyes, sinus pressure, tinnitus, runny nose, body odor, and intolerance to carbohydrates, specifically sugar and starches, but not low-carbohydrate vegetables. These are the most prominent signs.
A feeling of indigestion, heartburn, and reflux is very common in cases of fungal overgrowth in the digestive system. This has been seen a lot, especially the image of reflux and indigestion that is really stubborn and doesn't respond to conventional over-the-counter treatments or even natural remedies. Recurrent vaginal yeast infections, jock itch, and toenail fungus may also be clear enough symptoms to bring up for discussion.
Long-term use of antibiotics is a risk factor. Long-term is defined as months to years of previous antibiotic use, or multiple rounds thereof. Three to five rounds probably marks the threshold at which multiple rounds become a problem. Lack of breastfeeding, or breastfeeding for a very short period early in life, is another factor. Also, the lack of natural childbirth, and the early use of antibiotics. The earlier a child is given antibiotics, the greater the adverse effect on the microbiome. Adult microbes are more resistant to disruptions caused by things like antibiotics, while infant microbes are more susceptible to these adverse effects.
Antacids or proton pump inhibitors such as omeprazole, drugs often used for conditions such as heartburn and acid reflux, have been strongly associated with fungal overgrowth in the digestive tract. Antibiotics and proton pump inhibitors such as omeprazole can lead to fungal overgrowth. A single short course of antibiotic treatment has led to what is believed to be an overgrowth of fungi in patients. It is important to know if antibiotics and proton pump inhibitors are in medical history, and if this coincides chronologically with the onset of some symptoms.
Environmental exposure to mold or to buildings damaged by water is another method of colonization by a type of fungus, namely mold, which is perhaps the most important in terms of its harmful effect, and the precision that must be followed in treating it to get rid of it completely.
The quote "The enemy of success is confusion, and the ally of achievement is focus" is very relevant to people in this situation who are suffering from chronic symptoms that may be caused by fungi. They receive simple treatment; they may feel better, they may not. They may relapse later on, unsure whether they are on the right track.
Currently there are no official guidelines on this matter within the field of integrative medicine. This is one of the advantages and challenges of alternative, integrative and functional medicine, as there is a lot of exploration about how to better help patients. The downside is that no one has really come up with the best way in many of these areas, so there are no major associations that have established firm guidelines.
The infection tends to grow in two areas: the sinuses and intestines. Sinusitis is sometimes overlooked, but it is closely related to people with chronic neurological symptoms because a fungal infection in the sinuses has direct access to the brain, bypassing the filter and guard of the blood-brain barrier. Symptoms include eye pressure, red eyes, watery and itchy eyes, sinus congestion, nasal sinus pressure, tinnitus, sinus headache, jaw clicking, and chronic nasal discharge.
If there is a history of mold exposure, if a building that has had water damage or showed obvious signs of water damage, or was damp, smelled of mold, foggy, or damp with dew has been lived or worked in. A blood test for mold antibodies, not mycotoxins, is important because that is where there is better data that tells how to interpret antibodies and what is normal versus what is abnormal. If a sinus infection is suspected, a CT scan of the sinuses really completes this diagnostic picture.
The only mistake to emphasize is not placing the entire responsibility on a single laboratory test. Multiple things need to be looked at together. This mosaic of data gives an informed perspective on the likelihood of a fungal infection being present or not. This is a field where probabilities are dealt with, and this framework gives the highest degree of probability.
Even in the traditional literature for diagnosing pulmonary aspergillosis, a fungal infection of the lungs, CT scans, imaging and symptoms are used, but antibodies may be positive or negative. Antibodies are not relied upon solely. It is helpful if the percentage is high, but it is not used as the sole determinant. Other objective and subjective measures are used for assessment and diagnosis.
This diagnostic framework was not developed based on mere speculation. It was the result of the question: How do we do this with a good margin of confidence? What is being done in other areas that receive more research was looked at. Even in lung infections, the combination or compatibility between the antibodies and the CT scan results is looked at.
Herbs alone are not sufficient. This is mostly based on clinical observations where very intensive herbal treatment was being received and the decision was made to combine medications, which made a clear difference. There are no studies that have carefully controlled patients receiving only herbs versus medications just for comparison. If people are following treatments that help a large number of people and they are not responding, then other additional treatments should be incorporated. It is a multi-treatment approach. Combining them is really the best option.
The basic protocol includes clinical dosage of probiotics and support for the gut lining. Triple therapy and intestinal reconstruction are used. The goal is to promote the growth of beneficial bacteria in the gut. As long as probiotics, prebiotics, resistant starch and fiber are tolerated, many formulations are available. "Pyata Boost," "Pyata Resistant Starch," and "Pyata Fiber" are all good ideas for incorporating herbal antimicrobials.
The "Biotech Clear" protocol has been published using herbal antimicrobials with an anti-membrane agent, and it has shown impressive—albeit preliminary—results in the treatment of small intestinal bacterial overgrowth (SIBO). All of these herbs are actually antibacterial and antifungal at the same time.
The nasal rinse protocol includes the simple saline nasal rinse. The "Neomed" bottle has impressive data for reducing sinus inflammation. The Neil-Med squeeze bottle is recommended at least as part of the first level of the nasal rinse protocol, with the addition of Neil-Med xylitol. A NAC supplement can be added, as well as a probiotic called Livia One.
Herbs have been found particularly effective for fungal overgrowth in the digestive tract. Herbs work well for most people. The situation is different when talking about mold, that is, fungi or mold that has spread throughout the body, especially in the sinuses or even in the lungs at a low level. There is not enough data here on the use of natural substances or herbs to eliminate those fungi. If there was a fungal infection or overgrowth in the digestive tract in the first place, herbs were seen to work well, but at some point the patient regressed, and that's when a prescription antifungal was brought in that led to a sustained improvement in their symptoms.
Herbs can make a difference, but sometimes medication is necessary to overcome that obstacle and achieve sustained improvement. Either research is lacking, or herbs may not have the same ability to accumulate in certain tissues of the body. Combining methods together for people who do not respond to natural treatments gives a greater chance of success.
People have tried drugs such as fluconazole, nystatin, itraconazole, and possibly sporanox and have not responded. Problems with the absorption of itraconazole are well established in scientific research. There is a lot of data showing that generic itraconazole suffers from inconsistency in absorption. If 200 or 400 milligrams are being taken, it cannot be assumed that the necessary levels in the blood to kill the fungus are being obtained.
Tests conducted at the clinic measured the level of itraconazole in the blood. Of the four people assessed, none of them achieved the required therapeutic levels in the blood. One person continued with it for 6 months to a year, perhaps feeling a slight improvement. One of the main reasons for this may be that it is not absorbed well. Blood test results came back at one-tenth of the target therapeutic level. The dose of itraconazole cannot be increased enough to close this gap.
"Sporanox," which is the commercial version of "Itraconazole," has better absorption. It is better, but not perfect, and it is very difficult to get insurance coverage for this drug. Without that insurance coverage, it will cost $2,500 per month, and it must be taken for at least 3 months.
"Supaconazole," which is a newer generation of "Itraconazole" that has better absorption, has the same situation. Approval can be obtained if treating a fungal infection in the lungs. Apart from that, it is difficult to insure "Supaconazole." Its cash cost is $3,000 per month.
"Posaconazole" has better absorption, specifically the extended-release type, and it is superior in absorption to generic or commercial types of itraconazole or subitraconazole. It works against more types of fungi. The cash payment cost is $150 per month. This seems like a very logical option.
Open Evidence was used, which is a great medical artificial intelligence that major hospitals and academic research centers have integrated. It was a great tool, like having a PhD-level research assistant who could do hours of research and get an answer in 30 seconds.
Scott was asked to reach out to David Curry (DC) to learn about his experience with posaconazole. When they read DC's message, they felt immediate excitement. DC stated: "Posaconazole is a miracle drug. It has done amazing things for my patients. Complete cures for asthma and chronic sinusitis, put an end to years of hives, and ended allergies to various environmental factors, including foods. Lots of happy patients, and it is the safest and most effective antifungal I can get my hands on." This confirmation validated their approach and came from someone with years of clinical experience using the medication.
Posaconazole has evolved from a liquid formulation with acceptable absorption to much better slow-release tablets. With each formulation change and update, new research must be conducted to understand optimal use. The current standard recommendations from the Infectious Diseases Society of America (IDSA) recommend 300 milligrams daily. Research from parasitology protocols suggests adjusting doses based on body weight may achieve better blood levels. Studies confirm that weight-adjusted dosing improves therapeutic outcomes.
The standard dose is 300 milligrams per day. For patients weighing over 90 kilograms, the recommended dose is 200 milligrams twice a day, totaling 400 milligrams daily. This approach was illustrated through personal experience: despite taking 300 milligrams daily and having weight-adjusted dosing, blood levels measured 0.8 micrograms per milliliter, slightly below the target therapeutic level of 1 microgram per milliliter.
Standard guidelines provide a starting point but aren't always perfect, especially with new treatments where guidelines evolve over time. Without measuring therapeutic drug levels in blood, patients may not reach required therapeutic concentrations even when following guidelines. The importance of blood testing to confirm therapeutic levels cannot be overstated, particularly given that up to 30% of people with digestive symptoms or comorbidities show lower absorption rates.
Posaconazole is currently intended for patients who have failed to respond to fluconazole, typically more severely ill patient groups including those with cancer undergoing chemotherapy or immunosuppression. Evidence must guide treatment decisions but not bind them rigidly when translating to different patient populations.
When treating fungal infections and observing signs of fungal death, the inclination to start with low, slow doses is counterproductive. Subtherapeutic dosing spreads inflammation and cultivates more resistant infections. Research demonstrates that subtherapeutic doses cause more inflammation, increased cell death, greater illness symptoms, and increased treatment resistance. The analogy used: poking a wasps' nest daily causes continued stings, whereas aggressive extermination eliminates the nest despite temporary increased activity.
An inverted U-shape distribution illustrates the therapeutic window. At very low doses (subtherapeutic), minimal cell death occurs with little improvement. At intermediate levels around 0.5 micrograms per milliliter, inflammation and cell death persist throughout treatment as the infection is provoked without elimination. At therapeutic levels of 1 microgram per milliliter or higher, patients may experience 2 days of pronounced deterioration followed by significant improvement.
When taking 400 milligrams daily of posaconazole, there was a difficult 24-hour period with symptoms including heart racing, brain fog, exhaustion, and upper right quadrant discomfort. Despite initial worsening, blood level testing revealed subtherapeutic concentrations. Dose increase led to initial deterioration followed by marked improvement, with the patient reporting feeling mentally sharp and significantly better overall.
The internal struggle between continuing treatment versus retreating involves the prefrontal cortex (executive functions, long-term planning, tolerance of short-term discomfort for long-term gains) versus the limbic system (avoiding immediate pain, focusing on present moment). The limbic system says "This is not fun. I will stop doing that." The prefrontal cortex coordinates sacrifice of short-term comfort for long-term achievements.
Safety data for antifungal medications comes primarily from cancer patients and immunocompromised individuals taking multiple medications including chemotherapy, creating different interaction profiles than the patient population being treated. This context difference provides reassurance about the medication's safety profile in the current patient group.
Dr. Syd Baker's 2020 case study of an autistic child treated with alternating generic itraconazole and brand-name Sporanox demonstrated the principle clearly. The child worsened on generic medication (interpreted as Herxheimer reaction) and improved on Sporanox. The pattern repeated with each switch. The final effective dose reached 600 milligrams for a four-year-old child (adult recommended dose: 200-400 milligrams), with normal liver enzymes and elimination of autism symptoms. The worsening on generic medication was attributed to subtherapeutic levels, while Sporanox achieved therapeutic levels that eliminated the infection.
Open Evidence compilation of studies on subtherapeutic doses indicates exposure to fungi at sub-inhibitory doses exacerbates inflammation through two pathways: direct remodeling of the cell wall exposing immune-stimulating molecules like beta-glucans, leading to stronger innate immunity activation, and upregulation of innate virulence factors provoking increased host inflammatory response.
Of the first four patients whose serum levels were tested, all were significantly below therapeutic levels, with the highest at 0.4 micrograms per milliliter (target: 1). This suggests subtherapeutic dosing is more common than previously realized due to lack of testing. Patients who have tried diet, lifestyle changes, probiotics, and natural remedies, then turn to medications like itraconazole or Sporanox as a last resort, may have been unknowingly below therapeutic levels throughout treatment.
The fundamental principle: the danger lies not in moving forward more boldly, but in retreat. This applies within certain clinical limitations that may prevent aggressive dosing, but these represent exceptions rather than the rule.
The Clarity app provides cognitive behavioral therapy tools for managing catastrophic thoughts during treatment. Users enter distressing thoughts ("I feel pain in my liver. My liver is failing") and the app guides them through replacement with realistic, accurate statements. This tool helps patients stay on track during die-off symptoms by managing overthinking and catastrophic thinking patterns.
The medication must reach target tissue. Not all drugs accumulate in body tissues - rifaximin for SIBO treatment is designed not to accumulate in tissues. For infections in sinuses or deep intestinal basement membrane, systemic drugs that accumulate inside cells are required rather than topical treatments.
Dr. Pigmon's hypothesis suggests that inhaled mold may preferentially infect the basement membrane of intestinal cells rather than remaining in the lumen. Supporting evidence includes IgA antibody responses and Candida immune complex testing, indicating infections have penetrated deep enough into intestinal lining to trigger immune responses. Non-curative treatment rates in fungal infections range from 20-40%.
Scientific evidence supports the idea that an IgA antibody response, measured through the Candida immune complex test, indicates that Candida has penetrated beyond the intestinal lumen into the intestinal lining. This immune response shows the infection is not confined to the digestive tract lumen.
Non-curative treatment of fungal infections occurs in 20-50% of cases depending on measurement criteria. Relapse rates are similarly high, ranging from 20-50% of cases. These statistics emphasize the importance of eliminating all reservoirs of infection to prevent future spread. Multiple studies demonstrate that longer treatment duration correlates with better success rates and lower relapse rates.
Despite the effectiveness of Posaconazole, a critical weakness exists: the delayed-release tablet does not open and begin releasing until the end of the small intestine. This means the first portions of the small intestine receive no local antifungal effect from Posaconazole.
Amphotericin B serves as the antifungal equivalent of Rifaximin - a non-absorbable antibiotic used for intestinal bacterial overgrowth. As a non-absorbable antifungal, Amphotericin B provides local effect on the intestinal surface. This approach was informally explored through a protocol developed by Joseph Brewer, an infectious disease physician in Kansas City. Brewer published important work on nasal spray Amphotericin B for topical antifungal action in the sinuses, and his protocol evolved to combine nasal spray Amphotericin B with oral non-absorbable Amphotericin B for intestinal treatment.
While natural remedies are valuable, they may lack sufficient systemic absorption or fail to achieve high enough blood levels to effectively kill fungus. Posaconazole and similar pharmaceutical antifungals appear most effective for systemic treatment, and can be paired with topical Amphotericin B to achieve comprehensive cleansing throughout the gastrointestinal tract lumen.
Treatment duration typically spans three, six, or nine months, with improvement measured through symptom resolution and follow-up testing. However, some patients treated for a full year by attentive physicians report only slight improvement, which falls short of the complete symptom resolution goal.
Principle 1: Diagnostic Clarity - Undergo thorough diagnostic testing to confirm fungal involvement, as symptoms may stem from other causes.
Principle 2: Herbs Have Limitations - While herbs and natural medicines are routinely used and valuable, they alone are insufficient for complete fungal treatment.
Principle 3: Achieve Therapeutic Drug Levels - Pharmaceutical antifungals must reach therapeutic concentrations; standard dosing may not be adequate.
Principle 4: Maintain Aggressive Treatment - Retreat or withdrawal poses greater danger than forward progress; aggressive treatment offers the best chance of success.
Principle 5: Ensure Complete Tissue Coverage - Treatments must reach all target tissues, as missing portions of affected tissue may explain relapse and treatment failure.
The clinic provides second opinions for those needing additional expertise. The field of functional and integrative medicine includes many qualified mold specialists, though significant room for improvement exists in current approaches. The work continues to evolve based on personal motivation to overcome chronic health challenges.
Keep Dr. Michael Ruscio, DC, DNM in your library
Save the videos and channels worth coming back to, and find them again in one place.
